30 related articles for article (PubMed ID: 9732400)
1. Immunochemotherapy of malignant glioma: synergistic activity of CD95 ligand and chemotherapeutics.
Roth W; Fontana A; Trepel M; Reed JC; Dichgans J; Weller M
Cancer Immunol Immunother; 1997 Mar; 44(1):55-63. PubMed ID: 9111585
[TBL] [Abstract][Full Text] [Related]
2. CD95/Fas ligand mRNA is toxic to cells through more than one mechanism.
Haluck-Kangas A; Fink M; Bartom ET; Peter ME
Mol Biomed; 2023 Apr; 4(1):11. PubMed ID: 37059938
[TBL] [Abstract][Full Text] [Related]
3. Deneddylation of ribosomal proteins promotes synergy between MLN4924 and chemotherapy to elicit complete therapeutic responses.
Aubry A; Pearson JD; Charish J; Yu T; Sivak JM; Xirodimas DP; Avet-Loiseau H; Corre J; Monnier PP; Bremner R
Cell Rep; 2023 Aug; 42(8):112925. PubMed ID: 37552601
[TBL] [Abstract][Full Text] [Related]
4. Topotecan enhances immune clearance of gliomas.
Wei J; DeAngulo G; Sun W; Hussain SF; Vasquez H; Jordan J; Weinberg J; Wolff J; Koshkina N; Heimberger AB
Cancer Immunol Immunother; 2009 Feb; 58(2):259-70. PubMed ID: 18594817
[TBL] [Abstract][Full Text] [Related]
5. Induction of apoptosis in cells of the immune system by cytotoxic stimuli.
Cotter TG
Semin Immunol; 1992 Dec; 4(6):399-405. PubMed ID: 1286166
[TBL] [Abstract][Full Text] [Related]
6. Boswellic acids and malignant glioma: induction of apoptosis but no modulation of drug sensitivity.
Glaser T; Winter S; Groscurth P; Safayhi H; Sailer ER; Ammon HP; Schabet M; Weller M
Br J Cancer; 1999 May; 80(5-6):756-65. PubMed ID: 10360653
[TBL] [Abstract][Full Text] [Related]
7. The topoisomerase II inhibitor, genistein, induces G2/M arrest and apoptosis in human malignant glioma cell lines.
Schmidt F; Knobbe CB; Frank B; Wolburg H; Weller M
Oncol Rep; 2008 Apr; 19(4):1061-6. PubMed ID: 18357397
[TBL] [Abstract][Full Text] [Related]
8. Dexamethasone-mediated protection from drug cytotoxicity: association with p21WAF1/CIP1 protein accumulation?
Naumann U; Durka S; Weller M
Oncogene; 1998 Sep; 17(12):1567-75. PubMed ID: 9794234
[TBL] [Abstract][Full Text] [Related]
9. CCNU-dependent potentiation of TRAIL/Apo2L-induced apoptosis in human glioma cells is p53-independent but may involve enhanced cytochrome c release.
Röhn TA; Wagenknecht B; Roth W; Naumann U; Gulbins E; Krammer PH; Walczak H; Weller M
Oncogene; 2001 Jul; 20(31):4128-37. PubMed ID: 11464279
[TBL] [Abstract][Full Text] [Related]
10. The CD95/CD95 ligand system is not the major effector in anticancer drug-mediated apoptosis.
Tolomeo M; Dusonchet L; Meli M; Grimaudo S; D'Alessandro N; Papoff G; Ruberti G; Rausa L
Cell Death Differ; 1998 Sep; 5(9):735-42. PubMed ID: 10200532
[TBL] [Abstract][Full Text] [Related]
11. Potentiation of CD95L-induced apoptosis of human malignant glioma cells by topotecan involves inhibition of RNA synthesis but not changes in CD95 or CD95L protein expression.
Winter S; Weller M
J Pharmacol Exp Ther; 1998 Sep; 286(3):1374-82. PubMed ID: 9732400
[TBL] [Abstract][Full Text] [Related]
12. CD95 ligand: lethal weapon against malignant glioma?
Weller M; Kleihues P; Dichgans J; Ohgaki H
Brain Pathol; 1998 Apr; 8(2):285-93. PubMed ID: 9546287
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
